PharmaPoint: Melanoma – Global Drug Forecast and Market Analysis to 2026

Melanoma is the deadliest and most aggressive form of skin cancer. Melanoma is rare compared with other major cancer indications, but the incident cases are increasing because of the aging population and changes in lifestyle that result in more ultraviolet (UV) exposure.

Since 2011, the FDA/EMA have approved four immunotherapies, starting with the CTLA-4 targeting mAb, Yervoy (ipilimumab, Bristol-Myers Squibb), followed by PD-1 targeting mAbs, Keytruda (pembrolizumab, Merck & Co) and Opdivo (nivolumab, Ono/Bristol-Myers Squibb) and finally, oncolytic viral therapy, Imlygic (talimogene laherparepvec, Amgen). BRAF and MEK inhibitors were also first introduced to the market in 2011 (Novartis’s Tafinlar [dabrafenib] + Mekinist [trametinib] and Roche’s Zelboraf [vemurafenib] + Cotellic [cobimetinib]). Together, these new MOAs provide renewed hope to improve the treatment outcomes of melanoma patients. These agents will be utilized in early lines of metastatic therapy, and will continue to push the use of chemotherapy to later treatment lines. Although these new treatments have extended the survival of metastatic patients compared with chemotherapy-only regimens, high unmet needs remain for the non-responders to these targeted treatments, especially in BRAF WT patients who are ineligible for BRAF/MEK targeted therapies. A number of promising pipeline products, especially immune checkpoint inhibitors in combinations, will likely change the treatment landscape in the next few years.

Scope

Overview of melanoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized melanoma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments, forecast from 2016 to 2026.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the melanoma therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for melanoma. The most promising candidates in Phase III development are profiled.

Analysis of the current and future market competition in the global melanoma market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global melanoma market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global melanoma market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

AB Science

Amgen

Array BioPharma

AVAX Technologies

Bristol-Myers Squibb

Genentech

GlaxoSmithKline

Incyte

Merck & Co

Novartis

Ono Pharmaceutical

Philogen

Pierre Fabre

Polynoma

Provectus

Roche

Schering-Plough

AB Science

Amgen

Array BioPharma

AVAX Technologies

Bristol-Myers Squibb

Genentech

GlaxoSmithKline

Incyte

Merck & Co

Novartis

Ono Pharmaceutical

Philogen

Pierre Fabre

Polynoma

Provectus

Roche

Schering-Plough

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Modest Growth in ...

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Modest Growth in the Melanoma Market Expected from 2016–2026

2.2 Despite Strong Competition, Bristol-Myers Squibb to Remain the Leader of the Checkpoint Immunotherapy and Overall Melanoma Market

2.3 High Unmet Need Remains for Efficacious Treatment Options in BRAF Wild-Type Patients

2.4 High Commericial Opportunity for Adjuvant Treatments that Improve Cure Rates in Early-Stage, Resectable Melanoma Patients

2.5 Innovative Immune Checkpoint Inhibitor Combinations Strive for Market Penetration Due to a Crowded Melanoma Market

2.6 Late-Stage Pipeline Agents to Have Limited Impact on the Future Melanoma Landscape

2.7 What Do the Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.1.3 Melanoma Biomarkers

4.2 Clinical Staging

4.3 Symptoms

4.4 Prognosis

4.5 Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for Melanoma (2016–2026)

5.5.1 Diagnosed Incident Cases of Melanoma

5.5.2 Age-Specific Diagnosed Incident Cases of Melanoma

5.5.3 Sex-Specific Diagnosed Incident Cases of Melanoma

5.5.4 Five-Year Diagnosed Prevalent Cases of Melanoma

5.5.5 Diagnosed Incident Cases of Melanoma by Stage at Diagnosis

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis Overview

6.2 Treatment Guidelines, Leading Prescribed Drugs, and Clinical Practice

6.2.1 Localized Melanoma: Stage 0 to Stage IIc

6.2.2 Regional Melanoma: Stage IIIa to Stage IIIc

6.2.3 Advanced (Unresectable and Metastatic) Melanoma: Stage III and Stage IV

6.3 US

6.3.1 Screening and Diagnosis

6.3.2 Clinical Practices

6.4 France

6.4.1 Screening and Diagnosis

6.4.2 Clinical Practices

6.5 Germany

6.5.1 Screening and Diagnosis

6.5.2 Clinical Practices

6.6 Italy

6.6.1 Screening and Diagnosis

6.6.2 Clinical Practices

6.7 Spain

6.7.1 Screening and Diagnosis

6.7.2 Clinical Practices

6.8 UK

6.8.1 Screening and Diagnosis

6.8.2 Clinical Practices

6.9 Australia

6.9.1 Screening and Diagnosis

6.9.2 Clinical Practices

7 Competitive Assessment

7.1 Overview

7.2 Interferon-Based Adjuvant Therapies

7.2.1 Roferon-A (Interferon Alfa-2a)

7.2.2 Intron A (Interferon Alfa-2b)

7.2.3 Sylatron (Peginterferon Alfa-2b)

7.3 Immune Checkpoint Inhibitors

7.3.1 Yervoy (Ipilimumab)

7.3.2 Opdivo (Nivolumab)

7.3.3 Keytruda (Pembrolizumab)

7.4 BRAF and MEK Targeted Therapies

7.4.1 Zelboraf (Vemurafenib)

7.4.2 Cotellic (Cobimetinib)

7.4.3 Tafinlar (Dabrafenib)

7.4.4 Mekinist (Trametinib)

7.5 Oncolytic Viral Therapy

7.5.1 Imlygic (Talimogene Laherparepvec)

7.6 Other Therapeutic Classes

8 Unmet Need and Opportunity

8.1 Overview

8.2 Therapeutic Options for BRAF Wild-Type Patients

8.2.1 Unmet Need

8.2.2 Gap Analysis

8.2.3 Opportunity

8.3 Therapies for Non-responders to PD-1 Immunotherapy

8.3.1 Unmet Need

8.3.2 Gap Analysis

8.3.3 Opportunity

8.4 Neoadjuvant and Adjuvant Therapies for High-Risk Resectable Melanoma

8.4.1 Unmet Need

8.4.2 Gap Analysis

8.4.3 Opportunity

8.5 Effective Treatment for Brain Metastases

8.5.1 Unmet Need

8.5.2 Gap Analysis

8.5.3 Opportunity

8.6 Predictive Markers for Therapeutic Response to Immunotherapies

8.6.1 Unmet Need

8.6.2 Gap Analysis

8.6.3 Opportunity

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.3 Immune Checkpoint Inhibitors

9.3.1 Epacadostat

9.3.2 Tecentriq (Atezolizumab)

9.3.3 PDR-001

9.4 Molecular Targeted Therapies

9.4.1 Encorafenib (LGX818)

9.4.2 Binimetinib (MEK162)

9.4.3 Masitinib (AB-1010)

9.5 Other Immune-Related Therapies

9.5.1 Seviprotimut-L

9.5.2 PV-10

9.5.3 M-Vax

9.5.4 Daromun (L19-IL2 + L19-TNF)

9.6 Promising Drugs in Early-Stage Development

9.6.1 Immunotherapies

9.6.2 Molecular Targeted Therapies

9.6.3 Oncolytic Viral Therapies, Adoptive T-cell Therapies, and Immunostimulants

9.7 Other Drugs in Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Profiles

10.3.1 Bristol-Myers Squibb

10.3.2 Novartis

10.3.3 Merck & Co

10.3.4 Roche

10.3.5 Incyte

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers – US

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers – 5EU

11.4 Australia

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers – Australia

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.4 Forecasting Methodology

12.4.1 Diagnosed Melanoma Patients

12.4.2 Percent Drug-Treated Patients

12.4.3 Drugs Included in Each Therapeutic Class

12.4.4 Launch and Patent Expiry Dates

12.4.5 General Pricing Assumptions

12.4.6 Average Body Weight and Surface Area Across the 7MM

12.4.7 Individual Drug Assumptions

12.4.8 Pricing of Pipeline Agents

12.5 Primary Research – KOLs Interviewed for This Report

12.6 Primary Research – Prescriber Survey

12.7 About the Authors

12.7.1 Analyst

12.7.2 Therapy Area Directors

12.7.3 Epidemiologist

12.7.4 Epidemiology Reviewers

12.7.5 Global Director of Therapy Analysis and Epidemiology

12.7.6 Global Head and EVP of Healthcare Operations and Strategy

12.8 About GlobalData

12.9 Contact Us

12.10 Disclaimer

List of Tables

Table 1: Melanoma: Key Metrics in Seven Major Pharmaceutical Markets

Table 2: Pathologic Stage Definitions for Melanoma

Table 3: The ABCED Rule of Melanoma Detection ...

Table 1: Melanoma: Key Metrics in Seven Major Pharmaceutical Markets

Table 2: Pathologic Stage Definitions for Melanoma

Table 3: The ABCED Rule of Melanoma Detection

Table 4: Prognosis of Melanoma

Table 5: Risk Factors for Melanoma

Table 6: 7MM, Diagnosed Incident Cases of Melanoma, Men and Women, Ages ≥18 Years, Select Years 2016–2026

Table 7: 7MM, Five-Year Diagnosed Prevalent Cases of Melanoma, Men and Women, Ages ≥18 Years, Select Years 2016–2026

Table 8: Clinical Guidelines for Melanoma

Table 9: Most Prescribed Drugs for Melanoma in the Global Markets by Class, 2016

Table 10: Country Profile – US

Table 11: Country Profile – France

Table 12: Country Profile – Germany

Table 13: Country Profile – Italy

Table 14: Country Profile – Spain

Table 15: Country Profile – UK

Table 16: Country Profile – Australia

Table 17: Leading Treatments for Melanoma, 2016

Table 18: Product Profile – Roferon-A

Table 19: Efficacy of Roferon-A

Table 20: Safety of Roferon-A

Table 21: Roferon-A SWOT Analysis, 2016

Table 22: Product Profile – Intron A

Table 23: Efficacy of Intron A from the Phase III E1684 Trial

Table 24: Safety of Intron A (E1684, E1690, and E1694)

Table 25: Intron A SWOT Analysis, 2015

Table 26: Product Profile – Sylatron

Table 27: Efficacy of Sylatron from the EORTC 18991 Trial

Table 28: Head-to-Head Comparison Between Sylatron and Low-Dose Interferon

Table 29: Safety of Sylatron from the EORTC 18991 Trial

Table 30: Sylatron SWOT Analysis, 2015

Table 31: Product Profile – Yervoy

Table 32: Yervoy Key Regulatory and Reimbursement Milestones in the US Melanoma Market

Table 33: Yervoy Key Regulatory and Reimbursement Milestones in the EU Melanoma Market

Table 34: Yervoy Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market

Table 35: Efficacy of Yervoy from the Phase III CA184-002 Trial

Table 36: Comparison of Higher Dose Yervoy and DTIC from the CA184-024 Trial

Table 37: Network Meta-analysis of Yervoy in the Advanced Setting

Table 38: Efficacy Data Comparing Yervoy 3mg/kg to Yervoy 10mg/kg from the CA184-169 Trial

Table 39: Efficacy of Yervoy in the Adjuvant Melanoma Setting from the CA184-029 Trial

Table 40: Safety of Yervoy at 3mg/kg in the Advanced Melanoma Setting from the CA184-002 trial

Table 41: Safety Data Comparing Yervoy 3mg/kg to Yervoy 10mg/kg from the CA184-169 Trial

Table 42: Safety of Yervoy in the Adjuvant Setting from the CA184-029 Trial

Table 43: Yervoy SWOT Analysis, 2017

Table 44: Product Profile – Opdivo

Table 45: Opdivo’s Key Regulatory and Reimbursement Milestones in the US Melanoma Market

Table 46: Opdivo’s Key Regulatory and Reimbursement Milestones in the EU Melanoma Market

Table 47: Opdivo’s Key Regulatory Milestones in the Australian Melanoma Market

Table 48: Efficacy of Opdivo in 1L BRAF-WT Advanced Melanoma from the CheckMate 066 Trial

Table 49: Efficacy of Opdivo + Yervoy from the CheckMate 067 Trial

Table 50: Safety Data from the CheckMate 037 Trial

Table 51: Safety Data from the CheckMate 066 Trial

Table 52: Safety Data from the CheckMate 067 Trial

Table 53: Opdivo SWOT Analysis, 2017

Table 54: Product Profile – Keytruda

Table 55: Keytruda Key Regulatory and Reimbursement Milestones in the US Melanoma Market

Table 56: Keytruda Key Regulatory and Reimbursement Milestones in the EU Melanoma Market

Table 57: Keytruda Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market

Table 58: Survival Data from the Phase Ib KEYNOTE-001 Trial

Table 59: Efficacy of Keytruda from the KEYNOTE-002 Trial

Table 60: Efficacy of Keytruda from the KEYNOTE-006 Trial

Table 61: Efficacy of Keytruda in Combinations in the 1L Setting

Table 62: Safety Data from the KEYNOTE-001 Trial

Table 63: Safety of Keytruda from the KEYNOTE-002 Trial

Table 64: Safety Data from the KEYNOTE-006 Trial

Table 65: Safety of Keytruda in the 1L Setting from 2016 ASCO Annual Meeting

Table 66: Keytruda SWOT Analysis, 2017

Table 67: Product Profile – Zelboraf

Table 68: Zelboraf’s Key Regulatory and Reimbursement Milestones in the US Melanoma Market

Table 69: Zelboraf’s Key Regulatory and Reimbursement Milestones in the EU Melanoma Market

Table 70: Zelboraf’s Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market

Table 71: Efficacy of Zelboraf

Table 72: Safety of Zelboraf

Table 73: Zelboraf SWOT Analysis, 2017

Table 74: Product Profile – Cotellic

Table 75: Cotellic’s Key Regulatory and Reimbursement Milestones in the US Melanoma Market

Table 76: Cotellic’s Key Regulatory and Reimbursement Milestones in the EU Melanoma Market

Table 77: Cotellic’s Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market

Table 78: Efficacy of Cotellic in BRAF V600 Mutation-Positive Advanced Melanoma from the coBRIM Trial

Table 79: Safety Data of Cotellic from the coBRIM Trial

Table 80: Cotellic SWOT Analysis, 2017

Table 81: Product Profile – Tafinlar

Table 82: Tafinlar’s Key Regulatory and Reimbursement Milestones in the US Melanoma Market

Table 83: Tafinlar’s Key Regulatory and Reimbursement Milestones in the EU Melanoma Market

Table 84: Tafinlar’s Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market

Table 85: Efficacy of Tafinlar Monotherapy from the BREAK-3 Trial

Table 86: Safety of Tafinlar

Table 87: Tafinlar SWOT Analysis, 2017

Table 88: Product Profile – Mekinist

Table 89: Mekinist’s Key Regulatory and Reimbursement Milestones in the US Melanoma Market

Table 90: Mekinist’s Key Regulatory and Reimbursement Milestones in the EU Melanoma Market

Table 91: Mekinist’s Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market

Table 92: Efficacy of Mekinist from the Phase III METRIC Trial

Table 93: Efficacy Results of Tafinlar + Mekinist from the Phase II NCT01072175 Trial

Table 94: Efficacy Results of the COMBI-d Trial

Table 95: Efficacy Results of Tafinlar + Mekinist from the COMBI-v Trial

Table 96: Safety of Mekinist from the Phase III METRIC Trial

Table 97: Safety Results of the COMBI-d Trial

Table 98: Safety Results of the COMBI-v Trial

Table 99: Mekinist SWOT Analysis, 2017

Table 100: Product Profile – Imlygic

Table 101: Imlygic’s Key Regulatory and Reimbursement Milestones in the US Melanoma Market

Table 102: Imlygic’s Key Regulatory and Reimbursement Milestones in the EU Melanoma Market

Table 103: Imlygic’s Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market

Table 104: Efficacy of Imlygic from the Phase III OPTiM Trial

Table 105: Exploratory Subgroup Analyses from the Phase III OPTiM Trial

Table 106: Safety of Imlygic from the Phase III OPTiM Trial

Table 107: Imlygic SWOT Analysis, 2017

Table 108: Summary of Minor Therapeutic Classes, 2017

Table 109: Product Profile – Epacadostat

Table 110: Efficacy of Keytruda + Epacadostat from the Phase I/II KEYNOTE-037/ECHO-202 Trial

Table 111: Safety Data of Keytruda + Epacadostat from the Phase I/II KEYNOTE-037/ECHO-202 Trial

Table 112: Epacadostat SWOT Analysis, 2017

Table 113: Product Profile – Tecentriq

Table 114: Tecentriq SWOT Analysis, 2017

Table 115: Product Profile – PDR-001

Table 116: PDR-001 SWOT Analysis, 2017

Table 117: Product Profile – Encorafenib

Table 118: Efficacy of Encorafenib from the Phase III COLUMBUS Trial

Table 119: Safety of Encorafenib Regimens from the Phase III COLUMBUS Trial

Table 120: Encorafenib SWOT Analysis, 2017

Table 121: Product Profile – Binimetinib

Table 122: Efficacy of Binimetinib from the Phase III NEMO Trial

Table 123: Safety of Binimetinib from the Phase III NEMO Trial

Table 124: Binimetinib SWOT Analysis, 2017

Table 125: Product Profile – Masitinib

Table 126: Masitinib SWOT Analysis, 2017

Table 127: Product Profile – Seviprotimut-L

Table 128: Efficacy of Seviprotimut-L from the Phase II POL 89-38 Trial

Table 129: Seviprotimut-L SWOT Analysis, 2017

Table 130: Product Profile – PV-10

Table 131: Efficacy of PV-10 from the PV-10-MM-02 Trial

Table 132: Safety of PV-10

Table 133: PV-10 SWOT Analysis, 2017

Table 134: Product Profile – M-Vax

Table 135: Efficacy of M-Vax from the Phase I/II NCT00257465 Trial

Table 136: M-Vax SWOT Analysis, 2017

Table 137: Product Profile – Daromun (L19-IL2 + L19-TNF)

Table 138: Efficacy of Daromun from the Phase II NCT02076633 Trial

Table 139: Daromun SWOT Analysis, 2017

Table 140: Clinical Settings of Early-Stage Immunotherapies

Table 141: Clinical Settings of Early-Stage Next-Generation BRAF Inhibitors

Table 142: Clinical Settings of Early-Stage Drugs Targeting the PI3K/Akt/mTOR Pathway

Table 143: Clinical Settings of Early-Stage Drugs Targeting Cell Cycle Checkpoints

Table 144: Clinical Settings of Early-Stage Oncolytic Viral, Adoptive T-cell and Immunostimulants

Table 145: Drugs in Development, 2017

Table 146: Key Companies in the Melanoma Market in the 7MM, 2017

Table 147: BMS’ Melanoma Portfolio Assessment, 2017

Table 148: Novartis’ Melanoma Portfolio Assessment, 2017

Table 149: Merck & Co’s Melanoma Portfolio Assessment, 2017

Table 150: Roche’s Melanoma Portfolio Assessment, 2017

Table 151: Incyte’s Melanoma Portfolio Assessment, 2017

Table 152: Melanoma Market in the 7MM – Drivers, 2016–2026

Table 153: Melanoma Market in the 7MM – Barriers, 2016

Table 154: Key Events Impacting Sales for Melanoma in the US, 2016–2026

Table 155: Melanoma Market in the US – Drivers and Barriers, 2016–2026

Table 156: Key Events Impacting Sales for Melanoma in the 5EU, 2016–2026

Table 157: Melanoma Market in the 5EU – Drivers and Barriers, 2016–2026

Table 158: Melanoma Market in the 5EU – Country-Specific Drivers, 2016–2026

Table 159: Melanoma Market in the 5EU – Country-Specific Barriers, 2016–2026

Table 160: Key Events Impacting Sales for Melanoma in Australia, 2016–2026

Table 161: Melanoma Market in Australia – Drivers and Barriers, 2016–2026

Table 162: Key Launch Dates

Table 163: Key Patent Expiries

Table 164 Average Body Weight and Surface Area Across the 7MM

Table 165: High-Prescribing Physicians Surveyed by Country

List of Figures

Figure 1: Global Sales Forecast by Country for Melanoma in 2016 and 2026

Figure 2: Analysis of the Company Portfolio Gap in Melanoma During the ...

Figure 1: Global Sales Forecast by Country for Melanoma in 2016 and 2026

Figure 2: Analysis of the Company Portfolio Gap in Melanoma During the Forecast Period, 2016–2026

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents in Melanoma, 2016–2026

Figure 4: 7MM, Age-Standardized Diagnosed Incidence of Melanoma, Men, Ages ≥18 Years, 2006–2026

Figure 5: 7MM, Age-Standardized Diagnosed Incidence of Melanoma, Women, Ages ≥18 Years, 2006–2026

Figure 6: 7MM, Sources Used and Not Used to Forecast Diagnosed Incident Cases of Melanoma, 2016

Figure 7: 7MM, Sources Used to Forecast Five-Year Diagnosed Prevalent Cases of Melanoma, 2016

Figure 8: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Melanoma by Stage at Diagnosis, 2016

Figure 9: 7MM, Age-Specific Diagnosed Incident Cases of Melanoma, Men and Women, 2016

Figure 10: 7MM, Sex-Specific Diagnosed Incident Cases of Melanoma, Ages ≥18 Years, 2016

Figure 11: 7MM, Diagnosed Incident Cases of Melanoma by Stage at Diagnosis, Men and Women, Ages ≥18 Years, 2016

Figure 12: Treatment Flowchart for Localized Melanoma

Figure 13: Treatment Flowchart for Regional Melanoma

Figure 14: Treatment Flowchart for Recurrent Melanoma

Figure 15: Treatment Flowchart for Advanced Melanoma

Figure 16: Yervoy’s Development in Melanoma

Figure 17: Opdivo’s Recent and Future Development in Melanoma

Figure 18: Keytruda’s Development in Melanoma

Figure 19: Zelboraf’s Development in Melanoma

Figure 20: Cotellic’s Recent and Future Development in Melanoma

Figure 21: Tafinlar’s Development in Melanoma

Figure 22: Mekinist’s Development in Melanoma

Figure 23: Imlygic’s Development in Melanoma

Figure 24: Unmet Need and Opportunity in Melanoma, 2016

Figure 25: Overview of the Development Pipeline in Melanoma

Figure 26: Melanoma – Phase III Pipeline, 2017

Figure 27: Competitive Assessment of Late-Stage Pipeline Agents in Melanoma, 2016–2026

Figure 28: Clinical and Commercial Positioning of Epacadostat

Figure 29: Clinical and Commercial Positioning of Tecentriq

Figure 30: Clinical and Commercial Positioning of PDR-001

Figure 31: Clinical and Commercial Positioning of Encorafenib

Figure 32: Clinical and Commercial Positioning of Binimetinib

Figure 33: Clinical and Commercial Positioning of Masitinib

Figure 34: Clinical and Commercial Positioning of Seviprotimut-L

Figure 35: Clinical and Commercial Positioning of PV-10

Figure 36: Clinical and Commercial Positioning of M-Vax

Figure 37: Clinical and Commercial Positioning of Daromun

Figure 38: Global Sales of Branded Products for Melanoma by Company, 2016–2026

Figure 39: Company Portfolio Gap Analysis in Melanoma, 2016–2026

Figure 40: Global (7MM) Sales Forecast by Country for Melanoma in 2016 and 2026

Figure 41: Sales Forecast by Class for Melanoma in the US in 2016 and 2026

Figure 42: Sales Forecast by Class for Melanoma in the 5EU in 2016 and 2026

Figure 43: Sales Forecast by Class for Melanoma in Australia in 2016 and 2026

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports